Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) by Gemma Bruera et al.
RESEARCH ARTICLE Open Access
Worse prognosis of KRAS c.35 G > A mutant
metastatic colorectal cancer (MCRC) patients
treated with intensive triplet chemotherapy plus
bevacizumab (FIr-B/FOx)
Gemma Bruera1,2, Katia Cannita1, Daniela Di Giacomo2, Aude Lamy3, Thierry Frébourg4, Jean Christophe Sabourin5,
Mario Tosi4, Edoardo Alesse2, Corrado Ficorella1,2 and Enrico Ricevuto1,2*
Abstract
Background: Prognosis of KRAS wild-type and mutant metastatic colorectal cancer (MCRC) patients (pts) treated
with bevacizumab (BEV)-containing chemotherapy is not significantly different. Since specific KRAS mutations confer
different aggressive behaviors, the prognostic role of prevalent KRAS mutations was retrospectively evaluated in
MCRC pts treated with first line FIr-B/FOx, associating BEV to triplet chemotherapy.
Methods: Tumor samples were screened for KRAS codon 12, 13 and BRAF V600E mutations by SNaPshot and/or
direct sequencing. MCRC pts <75-years-old were consecutively treated with FIr-B/FOx: weekly 12 hour-timed-flat-
infusion/5-fluorouracil (900 mg/m2 on days 1,2, 8, 9, 15, 16,22, 23), irinotecan plus BEV (160 mg/m2 and 5 mg/kg,
respectively, on days 1,15); and oxaliplatin (80 mg/m2, on days 8,22). Pts were classified as liver-limited (L-L) and
other/multiple metastatic (O/MM). Progression-free survival (PFS) and overall survival (OS) were compared using the
log-rank test.
Results: Fifty-nine pts were evaluated at a median follow-up of 21.5 months. KRAS mutant pts: c.35 G > A, 15 (25.4%);
c.35 G > T, 7 (11.8%); c.38 G > A, 3 (5%); other, 3 (5%). KRAS wild-type, 31 pts (52.7%). The objective response rate (ORR),
PFS and OS were, respectively: c.35 G > A mutant, 71%, 9 months, 14 months; other than c.35 G > A mutants, 61%, 12
months, 39 months. OS was significantly worse in c.35 G > A pts compared to KRAS wild-type (P = 0.002), KRAS/BRAF
wild-type (P = 0.03), other MCRC patients (P = 0.002), other than c.35 G > A (P = 0.05), other codon 12 (P = 0.03) mutant
pts. OS was not significantly different compared to c.35 G > T KRAS mutant (P = 0.142).
Conclusions: KRAS c.35 G > A mutant status may be significantly associated with a worse prognosis of MCRC pts
treated with first line FIr-B/FOx intensive regimen compared to KRAS/BRAF wild type and other than c.35 G > A
mutant pts.
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Background
KRAS genotype, wild-type or mutant, addresses the
medical treatment of metastatic colorectal cancer
(MCRC) patients (pts), consisting of triplet regimens
combining chemotherapeutic drugs, or doublets plus
targeted agents [1]. The addition of anti-epidermal
growth factor receptor (anti-EGFR) treatment is not
effective in KRAS mutant patients [2,3]; anti-vascular
endothelial growth factor (anti-VEGF) treatment added
to doublet chemotherapy was effective in KRAS wild-
type and mutant pts [4,5]. In liver limited (L-L) MCRC,
these first line options, integrated with secondary resec-
tion of liver metastases, may significantly increase survi-
val [6-13].
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The prognostic relevance of the KRAS genotype can be
assessed by evaluation of clinical outcome (progression-
free survival (PFS), overall survival (OS)) in wild-type and
mutant pts, depending on differential tumor biological
aggressiveness and predictive effectiveness of treatment
strategies. The median OS of KRAS wild-type and mutant
MCRC pts treated with irinotecan, 5-fluorouracil and
leucovorin (IFL) plus bevacizumab (BEV) was 27.7 and
19.9 months, respectively [4,5]. The hazard ratio (HR) for
risk of death was 0.51 and statistically significant only
when KRAS and BRAF wild-type pts were compared with
pts harboring mutations in one gene. In KRAS wild-type
pts and in BRAF wild-type pts compared to mutant, HR
was 0.64 and 0.38, respectively, but did not reach statisti-
cal significance [4]. Recently, phase II studies proposed
by Masi et al. [8], and by our group [7], showed that
intensive medical treatment consisting of triplet che-
motherapy plus BEV, according to FOLFOXIRI plus BEV
and FIr-B/FOx schedules, respectively, may increase the
activity and efficacy of the treatment in MCRC pts with
the KRAS wild-type and mutant genotypes [8,13]. Median
OS of pts treated with FIr-B/FOx was different in KRAS
wild-type and mutant pts (38 months and 21 months,
respectively), but not significantly [13]. L-L pts compared
to other/multiple metastatic (O/MM) pts achieve signifi-
cantly increased PFS and OS; in addition, KRAS wild-
type pts with L-L disease may achieve a significantly
greater benefit from integration with liver metastasec-
tomies, with respect to KRAS mutant patients [11,13].
The KRAS wild-type genotype predicts favorable clinical
outcomes when anti-EGFR or anti-VEGF molecules are
added to doublet chemotherapy [2,5]. The KRAS mutant
genotype significantly predicts prolonged PFS up to
9.3 months, while there was no increase in OS and activity
[14,5], in pts treated with BEV added to IFL compared to
IFL.
KRAS mutations occur in 35% to 45% of colorectal can-
cer (CRC), mostly in codon 12 (80%), c.35 G > A (G12D)
and c.35 G > T (G12V) transversions, representing 32.5%
[14,15] and 22.5% [14,16], respectively, and codon 13,
predominantly c.38 G > A (G13D) mutations [17]. These
mutations impair the intrinsic GTPase activity of KRAS,
thus leading to constitutive, growth-factor-receptor inde-
pendent activation of downstream signalling [18]. In the in
vitro model proposed by Guerrero et al. [19], codon 12
mutations increase aggressiveness by the differential regu-
lation of KRAS downstream pathways that lead to inhibi-
tion of apoptosis, enhanced loss of contact inhibition and
increased predisposition to anchorage-independent growth
[19]. Codon 13 mutations showed reduced transforming
capacity compared to codon 12 mutations [20].
The biological aggressiveness of codon 12 KRAS
mutant tumors seems to confer worse clinical behavior.
A multivariate analysis suggested that the presence of
KRAS mutation significantly increased the risk of recur-
rence and death; the codon 12 c.35 G > T (G12V) muta-
tion retained an independent increased risk of recurrence
and death [21], and significantly reduced disease-free sur-
vival and OS of Dukes C pts [16]. The poorer prognosis
conferred by codon 12 KRAS mutations was not con-
firmed in other studies [22,23].
We report a retrospective exploratory analysis evaluating
the prognostic value of the prevalent codon 12 c.35 G > A
(G12D) KRAS mutation in MCRC pts enrolled in a pre-
viously reported phase II study [7] and in an expanded
clinical program proposing FIr-B/FOx intensive regimen
as first line treatment.
Methods
Patient eligibility
MCRC pts were enrolled in a previously reported phase
II study [7] and in the expanded clinical program propos-
ing FIr-B/FOx association as first line treatment. The
study was approved by the Local Ethical Committee
(Comitato Etico, Azienda Sanitaria Locale n.4 L’Aquila,
Regione Abruzzo, Italia) and conducted in accordance
with the Declaration of Helsinki. All patients provided
written, informed consent.
Schedule
FIr-B/FOx association consisted of 5-fluorouracil asso-
ciated with alternating irinotecan/BEV or oxaliplatin,
according to a previously reported weekly schedule [7].
Mutation analysis
KRAS and BRAF analyses were performed on paraffin-
embedded tissue blocks from the primary tumor and/or
metastatic site. Genotype status was analyzed for KRAS
codon 12 and 13 mutations and BRAF c.1799 T > A
(V600E) mutation by SNaPshot® multiplex [13,24], for
KRAS mutations and KRAS/BRAF mutations in 36 and
32 samples, respectively; direct sequencing of the KRAS
gene was performed in 23 samples. After treatment with
xylene thiocyanate and selection of tumor cell clusters,
DNA was isolated using the RecoverAll™ Total Nucleic
Acid Isolation Kit for FFPE Tissues (Applied Biosystems,
Courtaboeuf, France) according to the manufacturer’s
instructions.
SNaPshot® assay
SNaPshot® multiplex assay was performed as previously
reported [13,25]. KRAS exon 2 and BRAF exon 15 were
simultaneously PCR-amplified and analyzed for the pre-
sence of mutations at KRAS nucleotides c.34G, c.35G,
c.37G, c.38G and BRAF mutation at nucleotide c.1799T
using the ABI PRISM SNaPshot® Multiplex kit (Applied
Biosystems, Foster City, CA, USA) [13,25]. Labelled pro-
ducts were separated on 36 cm-long capillaries in POP7
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polymer during a 25-minute run in an ABI Prism 3130xl
Genetic Analyzer (Applied Biosystems). Data were ana-
lyzed using the GeneMapper Analysis Software version 4.0
(Applied Biosystems).
Direct sequencing assay
KRAS exon 2 sequence reaction was performed from PCR-
amplified tumor DNA, using the Big Dye V3.1 Terminator
Kit (Applied Biosystems), and run on an automated
sequencer (ABI 3130, Applied Biosystems).
Study design
A retrospective analysis has been planned to evaluate the
prognostic relevance of the prevalent codon 12 c.35 G > A
(G12D) KRAS mutant genotype on the clinical outcome of
MCRC pts treated with first line FIr-B/FOx. Pts were clas-
sified as L-L and O/MM [13]. Clinical criteria of activity
and efficacy were ORR, PFS and OS. ORR was evaluated
according to Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [26]; pathological complete response was
defined as absence of residual cancer cells in surgically
resected specimens. Overall activity of integrated medical
treatment and secondary liver surgery, consisting of the
sum of clinical complete responses (cCR) and liver metas-
tasectomies was also evaluated, as previously reported
[11]. PFS and OS were evaluated using the Kaplan and
Meier method [27]. The log-rank test was used to com-
pare PFS and OS in different subgroups of pts [28]. PFS
was defined as the length of time between the beginning
of treatment and disease progression or death (resulting
from any cause) or to last contact; OS, as the length of
time between the beginning of treatment and death or to
last contact. Clinical evaluation of response was made by
computerized tomography (CT)-scan; positron emission
tomography (PET) was added based on the investigators’
assessment. Pts with L-L metastases were evaluated at
baseline and every three cycles of treatment, by a multidis-
ciplinary team (medical oncologist, liver surgeon, radiolo-
gist) to dynamically evaluate resectability, defined
according to previously reported resectability categories
[11]. The resection rate was evaluated in intent-to-treat
population enrolled. Liver metastasectomies were defined
as: R0, if radical surgery; R1, if radiofrequency was added.
Results
Patient demographics
The KRAS/BRAF genotype was evaluated in 59 pts, among
64 consecutive, unselected MCRC pts recruited in the
phase II study and expanded clinical enrollment of the
FIr-B/FOx regimen as the first line treatment of MCRC
[7,13]: 31 pts (53%) were identified as KRAS wild-type and
28 (47%) as KRAS mutant [13]. The prevalence of KRAS
mutations was: codon 12, 24 pts (40.6%), specifically c.35
G > A (G12D), 15 pts (25.4%), c.35 G > T (G12V), 7 pts
(11.8%), c.34 G > A (G12S) and c.35 G > C (G12A),
1 patient each; codon 13, 4 pts (6.7%), c.38 G > A (G13D),
3 pts (5%) and c.37_39 dupl, 1 patient (Table 1).
Table 2 describes the demographic and baseline features
of pts with the c.35 G > A KRAS mutation, other KRAS
mutations, and KRAS wild-type: male/female ratio, 11/4,
5/8 and 21/10, respectively; liver metastases, 12 (80%),
8 (61.5%) and 19 pts (61%), respectively.
Pts’ distribution according to extension of metastatic
disease in c.35 G > A KRAS mutant, other KRAS mutant,
and KRAS wild-type pts was, respectively: L-L 6 pts
(40%), 7 pts (54%), and 12 pts (39%); O/MM 9 pts (60%),
6 pts (46%), 19 pts (61%).
Activity and efficacy according to specific KRAS mutations
Activity and efficacy data in overall KRAS wild-type and
mutant pts at a median follow-up of 21.5 months were
previously reported [13]. Among 14 evaluable c.35 G > A
KRAS mutant pts (Table 3), ORR was 71% (a 0.05,
CI ± 26). We observed 10 objective responses: 9 partial
responses (64%) and 1 complete response (CR) (7%) in a
patient with single liver metastasis, who was progression-
free at 60 months; 3 stable diseases (21%); 1 progressive
disease (7%). Median PFS was 9 months (1+-60+ months):
10 events occurred and 5 pts (33%) were progression-free.
Median OS was 14 months (1+-60+ months): 10 events
occurred and 5 pts (33%) were alive. Liver metastasec-
tomies were performed in 2 pts out of 15 (13%) and out of
6 pts with L-L metastases (33%); 1 R0 liver metastasect-
omy (17%). Clinical outcome according to extension of
metastatic disease, L-L and O/MM [11,13], was: median
PFS 9 and 7 months, median OS 11 and 14 months,
respectively.
Among 13 other than c.35 G > A KRAS mutant pts,
ORR was 61% (a 0.05, CI ± 30). We observed 8 partial
responses (61%), 2 stable diseases (15%), and 3 progres-
sive diseases (23%). Median PFS was 12 months (3-37
months): 12 events occurred and 1 patient (8%) was pro-
gression-free >12 months. Median OS was 39 months
(8-59+ months): 8 events occurred and 5 pts (38%) were
Table 1 KRAS mutations
KRAS mutant
Exon Codon Hot spot site Amino acid No. of patients %
2 12 24 40.6
c.34 G > A p.Gly12Ser 1 1.6
c.35 G > A p.Gly12Asp 15 25.4
c.35 G > T p.Gly12Val 7 11.8
c.35 G > C p.Gly12Ala 1 1.6
13 4 6.7
c.37_39 dupl p.Gly13dupl 1 1.6
c.37 - - -
c.38 G > A p.Gly13Asp 3 5
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alive. Liver metastasectomies were performed in 5 pts out
of 13 (38%) and out of 7 (71%) with L-L metastases; 4 R0
liver resections (57%). Two pathologic CRs were obtained
(15%) in pts with multiple L-L metastases, harboring
codon 12 mutations, c.35 G > T and c.34 G > A: 1 patient
progressed at 17 months, 1 patient was progression-free
at 35 months. Clinical outcome according to extension of
metastatic disease, L-L and O/MM [11,13], was: median
Table 2 Patients’ features
c.35 G>A KRAS mutant Other KRAS mutant KRAS wild-type
Total Number (%) Total Number (%) Total Number (%)
Number of patients 15 (25) 13 (22) 31 (53)
Sex
male/female 11/4 5/8 21/10
Age, years
median 67 63 64
range 51 to 73 48 to 71 42 to 73
≥65 years 8 (53) 5 (38) 13 (42)
WHO Performance Status
0 13 (87) 13 (100) 28 (90)
1-2 2 (13) - 3 (10)
Metastatic disease
metachronous 5 (33) 2 (15) 10 (32)
synchronous 10 (67) 11 (85) 21 (68)
Primary tumor
colon 10 (67) 10 (77) 14 (45)
rectum 5 (33) 3 (23) 17 (55)
Sites of metastases
liver 12 (80) 8 (61.5) 19 (61)
lung 3 (20) 2 (15) 7 (23)
lymph nodes 4 (27) 4 (31) 10 (32)
local 2 (13) 1 (8) 6 (19)
other 4 (27) 2 (15) 2 (6)
Number of involved sites
1 8 (53) 9 (69) 17 (55)
≥2 7 (47) 4 (31) 14 (45)
Single metastatic sites
liver-limited 6 (40) 7 (54) 12 (39)
other than liver 2 (13) 2 (15) 7 (22)
lung 1 (6.5) 1 (8) 2 (6)
lymph nodes - 1 (8) 2 (6)
Local 1 (6.5) - 3 (10)
multiple metastatic site 7 (47) 4 (31) 12 (39)
Liver metastases
single 2 (13) 1 (8) 8 (26)
multiple 10 (67) 7 (54) 11 (35)
Previous adjuvant chemotherapy: 1 (6.5) 1 (8) 6 (19)
FA/5-FU bolus - - 3 (10)
Capecitabine - - -
FOLFOX4 1 (6.5) 1 (8) 2 (6)
XelOx - - 1 (3)
Previous radiotherapy: 1 (6.5) - 4 (13)
RT alone - - -
RT+CT (5-FU c.i.) - - 2 (6)
RT+CT (XELOX) 1 (6.5) - 2 (6)
c.i., continuous infusion; WHO, World Health Organization.
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PFS 16 and 12 months and median OS 44 and 21
months, respectively.
Activity and efficacy among 30 evaluable KRAS wild-type
pts was previously reported [13]: ORR was 90% (a 0.05, CI
± 11). Four cCR were obtained (13%): 1 patient progressed
at 22 months; 3 pts were progression-free at 69, 40 and
4 months. Median PFS was 14 months (1+-69+ months).
Median OS was 38 months (1+-69+ months). Liver metas-
tasectomies were performed in 11 pts: 35% of wild-type
MCRC pts and 10 out of 12 L-L pts (83%). Among 18
KRAS/BRAF wild-type pts [13], ORR was 83% (a 0.05, CI
± 14). Median PFS was 13 months (4-44 months), median
OS was 31 months (8-66+ months).
Among 44 evaluable other than c.35 G > A KRAS
mutant plus KRAS wild-type pts, ORR was 81% (a 0.05,
CI ± 12), median PFS was 13 months (1+-69+ months)
and median OS was 34 months (1+-69+ months)
(Table 4). Among 21 evaluable codon 12 KRAS mutant
pts, ORR was 71% (a 0.05, CI ± 20), median PFS
was 12 months (1+-60+ months) and median OS was
20 months (1+-60+ months). Among 7 c.35 G > T KRAS
mutant pts, ORR was 57% (a 0.05, CI ± 40), median PFS
was 12 months (3-5 months) and median OS was
21 months (11-46+ months). Among 4 codon 13 KRAS
mutant pts, ORR was 75% (a 0.05, CI ± 49), median PFS
was 12 months (7-37 months) and median OS was
44 months (8-59+ months). Among 3 c.38 G > A KRAS
mutant pts, ORR was 67% (a 0.05, CI ± 65), median PFS
was 12 months (7-37 months) and median OS was not
reached (8-59+ months).
Figure 1 shows that PFS of c.35 G > A KRAS mutant
pts compared to KRAS wild-type pts was not significantly
different while OS was significantly worse (P = 0.002).
In addition, c.35 G > A KRAS mutant pts compared to
other than c.35 G > A KRAS mutant pts showed signifi-
cantly worse OS (P = 0.05); other than c.35 G > A KRAS
mutant pts compared to KRAS wild-type pts did not have
different OS (Figure 2). KRAS c.35 G > A mutant pts also
had significantly worse OS compared to: other than c.35
G > A KRAS mutant pts plus KRAS wild-type pts (P =
0.002); KRAS/BRAF wild-type pts (P = 0.03); and other
codon 12 mutant pts (P = 0.03) (Figure 3). The prognos-
tic relevance was not significantly different compared to
c.35 G > T KRAS mutant pts (P = 0.142) (Figure 3).
Discussion
The prognostic relevance of KRAS status, wild-type or
mutant, is not significantly different in MCRC pts treated
with BEV-containing chemotherapy. Reported median
OS ranges from 29.9 to 38 months in KRAS wild-type
and 19.9 to 21 months in KRAS mutant pts [4,5,8,13].
The addition of anti-EGFR or anti-VEGF molecules to
doublet chemotherapy predicts a favorable clinical out-
come in KRAS wild-type pts [2,5]. BEV addition to IFL












Number % Number % Number %
Enrolled pts 15 100 13 100 31 100
Evaluable pts 14 93 13 100 30 97
Objective response 10 71 (CI ± 26) 8 61 (CI ± 26) 27 90 (CI ± 11)
partial response 9 64 8 61 23 76
complete response 1 7 - - 4 13
Stable disease 3 21 2 15 2 7
Progressive disease 1 7 3 23 1 3
Median PFS, months 9 12 14
range 1+-60+ 3-37 1+-69+
progression events 10 67 12 92 25 81
Median OS, months 14 39 38
range 1+-60+ 8-59+ 1+-69+
deaths 10 67 8 61.5 17 55
Liver metastasectomies 2 5 11
number/overall pts 2/15 13 5/13 38 11/31 35
number/Pts with liver metastases 2/12 17 5/8 62.5 11/19 58
number/Pts with L-L metastases 2/6 33 5/7 71 10/12 83
Pathologic complete responses - - 2 40 - -
L-L, liver-limited; OS, overall survival; PFS, progression-free survival; pts, patients.
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compared to IFL significantly predicts prolonged PFS up
to 9.3 months, but not increased OS and activity, in
KRAS mutant pts [5,14]. BEV addition to triplet che-
motherapy, according to FIr-B/FOx or FOLFOXIRI/BEV
schedules, resulted in high activity and efficacy in KRAS
wild-type and mutant MCRC pts [8,13]. In particular,
KRAS mutant pts had an ORR of 67% and 71%, median
PFS of 11 and 12.6 months, and median OS 20 months,
respectively [8,13]. We recently reported a significantly
favorable prognosis (PFS and OS) in KRAS wild-type L-L
compared to O/MM pts [11,13]. Conversely, in KRAS
mutant MCRC pts, median PFS and OS were not signifi-
cantly affected by the extension of metastatic disease
(L-L compared to O/MM) [11,13].
The prevalent c.35 G > A (G12D) KRAS mutation
characterizes 10.3% of CRC and represents up to 30% of
KRAS mutations [16]. In the present evaluation, 25.4%
of MCRC pts harbored the c.35 G > A KRAS mutation
and exhibited a high activity of the FIr-B/FOx intensive
regimen (ORR 71%). Liver metastasectomies were per-
formed in 13% of pts (33% of L-L disease), median PFS
and OS were 9 and 14 months, respectively. In pts with
the KRAS c.35 G > A mutation, activity and PFS were
not significantly different, while OS was significantly
worse compared to KRAS wild-type, KRAS/BRAF wild-
type, and other codon 12 and 13 mutant pts. Median
OS was not significantly different in other KRAS mutant
compared to wild-type pts. This is the first report of a
Table 4 Activity and efficacy according to KRAS genotype (intent-to-treat analysis)




KRAS wild-type plus other than c.35 G>A KRAS mutant (44 pts) 81 (CI ± 12) 13 34
1+-69+ 1+-69+
KRAS wild-type (30 pts) 90 (CI ± 11) 14 38
1+-69+ 1+-69+
KRAS wild-type/BRAF wild-type (18 pts) 83 (CI ± 14) 13 31
4-44 8-66+
other than c.35 G>A KRAS mutant (13 pts) 61 (CI ± 30) 12 39
3-37 8-59+
c.35 G>A KRAS mutant (14 pts) 71 (CI ± 26) 9 14
1+-60+ 1+-60+
c.35 G>T KRAS mutant (7 pts) 57 (CI ± 40) 12 21
3-25 11-46+
m, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
           
            
             (1)                                                      (2)  
Figure 1 Kaplan-Meier survival estimate. c.35 G > A KRAS mutant patients versus KRAS wild-type patients. 1, progression-free survival; 2,
overall survival.
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worse prognosis in KRAS c.35 G > A (G12D) mutant
MCRC pts, treated with intensive triplet chemotherapy
plus BEV.
Codon 12 KRAS mutations may increase aggressiveness
by the differential regulation of KRAS downstream path-
ways associated with higher AKT/protein kinase B activa-
tion, bcl-2, E-catherin, b-catenin, and focal adhesion
kinase overexpression, and RhoA underexpression,
whereas codon 13 KRAS mutant cells show increased
sensitivity associated with increased activation of the c-
Jun-NH2-terminal kinase I pathway [19]. Several studies
compared the prognostic roles of KRAS codon 12 with
codon 13 mutations in CRC. RASCAL (Kirsten Ras in
CRC) studies showed that the presence of the KRAS
mutation significantly increased the risk of death by 26%
[16,21]; the c.35 G > T (G12V) mutation, but not c.35
G > A (G12D) or c.35 G > C (G12A), represented an
independent risk factor for recurrence and death and sig-
nificantly increased the risk of death by 44% [21]. It also
had a significantly worse impact on failure-free survival
and OS, increasing the risk of recurrence or death by
30% [16], and up to 50% in Dukes’ C cancers [16]. KRAS
codon 12 mutations (in particular, c.35 G > T) were asso-
ciated with inferior survival in patients with KRAS-wild-
type/BRAF-wild-type cancers [29].
In MCRC pts, specific BRAF and KRAS mutations can
confer different biological aggressiveness and effectiveness
of treatment strategies; the balance between aggressiveness
and effectiveness can differentiate prognosis, that is, med-
ian OS. Comparison of median OS in pts with different
genotypes can discriminate this net prognostic effect.
Thus, specific mutations and treatment strategies (medical
regimens and secondary liver surgery, further lines of treat-
ment) could be major parameters determining different
prognoses in MCRC. The prevalent BRAF c.1799 T > A
(V600E) mutation, characterizing 4.7% to 8.7% of CRC,
demonstrated a negative prognostic effect compared to
BRAF wild-type pts in MCRC pts treated with doublet che-
motherapy alone or added to cetuximab, BEV and cetuxi-
mab plus BEV, with a median PFS of 5.6 to 8 months and
median OS of 10.3 to 15.9 months [4,30,31]. The favorable
predictive effect of cetuximab or BEV addition to che-
motherapy was not significantly demonstrated in BRAF
mutant MCRC pts [4,31,32]. Patients with tumors harbour-
ing the KRAS c.35 G > T mutation and other mutations
were associated with a worse outcome when receiving che-
motherapy plus cetuximab, compared with chemotherapy
alone [33].
In MCRC pts pre-treated with chemotherapy alone, the
KRAS c.38 G > A mutation (G13D) confers a significantly
worse prognosis [34]. Cetuximab or cetuximab plus che-
motherapy significantly predicted increased OS (median
7.6 and 10.6 months, respectively) and PFS (median 4.0
and 4.1 months, respectively) compared to other KRAS
mutations [34], and no different outcome was found
compared to KRAS wild-type pts [34]. Recently, a retro-
spective pooled analysis confirmed the favorable predic-
tive effect of c.38 G > A KRAS mutation in first line
cetuximab-containing chemotherapy [33]: significantly
improved PFS (median, 7.4 versus 6.0 months) and
tumor response (40.5% versus 22.0) but not survival
(median, 15.4 versus 14.7 months). Moreover, systematic
  
                (A)                                                 (B) 
Figure 2 Overall survival, Kaplan-Meier survival estimate. A, c.35 G > A KRAS mutant patients versus other KRAS mutant patients; B, other
KRAS mutant patients versus KRAS wild-type patients.
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reviews and meta analyses confirmed that KRAS c.38 G >
A (G13D) mutant pts demonstrated a significantly favor-
able predictive effect of cetuximab-containing associa-
tions compared to other KRAS mutant MCRC, and
significantly lower ORR, with no significantly different
PFS and OS compared to KRAS wild-type pts [35,36]. In
patients with MCRC treated with panitumumab or con-
trol therapy in first-or second-line chemorefractory set-
tings, no consistent associations were found between
tumors with specific KRAS mutations and patient out-
come. Opposite findings were reported when panitumu-
mab was combined with first line oxaliplatin, whereas
similar data were reported when it was combined with
second-line FOLFIRI [37].
Prospective studies should be developed to confirm
the differential prognosis and predictive effect of che-
motherapeutics and/or targeted agents in MCRC pts
harboring KRAS/BRAF mutations, specifically KRAS c.35
       
                   
              (A)                                                       (B)  
  
         
                 
                         (C)      (D) 
Figure 3 Overall survival, Kaplan-Meier survival estimate. A, c.35 G > A KRAS mutant patients versus other KRAS mutant plus KRAS wild-type
patients; B, c.35 G > A KRAS mutant patients versus KRAS/BRAF wild-type patients; C, c.35 G > A KRAS mutant patients versus other codon 12
KRAS mutant patients; D, c.35 G > A KRAS mutant patients versus c.35 G > T KRAS mutant patients.
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G > A (G12D), c.35 G > T (G12V), c.38 G > A (G13D)
mutations and BRAF c.1799 T > A (V600E).
Conclusions
The prevalent KRAS c.35 G > A (G12D) mutant genotype
has a significantly worse effect on the OS of MCRC pts
treated with the first line FIr-B/FOx intensive regimen
compared to wild-type pts or to pts harboring different
other KRAS mutations, due to heterogeneous biological
aggressiveness and the effectiveness of treatment strate-
gies. The present findings should be verified in prospec-
tive trials of multidisciplinary strategies comparing
clinical outcome in MCRC pts harboring specific muta-
tions that differentially activate the downstream RAS-
MAPK or PI3K pathways.
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